Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A protein puzzle: Untangling the mysterious condition of amyloidosis

A Correction to this article was published on 07 April 2017

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Change history

  • 23 March 2017

    In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis’ NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIOTTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chakradhar, S. A protein puzzle: Untangling the mysterious condition of amyloidosis. Nat Med 23, 266–269 (2017). https://doi.org/10.1038/nm0317-266

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0317-266

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing